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Abstract
Background: Retraction of nerve terminals is a characteristic feature of development, injury and
insult and may herald many neurodegenerative diseases. Although morphological events have been
well characterized, we know relatively little about the nature of the underlying cellular machinery.
Evidence suggests a strong local component in determining which neuronal branches and synapses
are lost, but a greater understanding of this basic neurological process is required. Here we test
the hypothesis that nerve terminals are semi-autonomous and able to rapidly respond to local
stimuli in the absence of communication with their parent cell body.
Results: We used an isolated preparation consisting of distal peripheral nerve stumps, associated
nerve terminals and post-synaptic muscle fibres, maintained in-vitro for up to 3 hrs. In this system
synapses are intact but the presynaptic nerve terminal is disconnected from its cell soma. In control
preparations synapses were stable for extended periods and did not undergo Wallerian
degneration. In contrast, addition of purines triggers rapid changes at synapses. Using fluorescence
and electron microscopy we observe ultrastructural and gross morphological events consistent
with nerve terminal retraction. We find no evidence of Wallerian or Wallerian-like degeneration
in these preparations. Pharmacological experiments implicate pre-synaptic P2X7 receptor subunits
as key mediators of these events.
Conclusion: The data presented suggest; first that isolated nerve terminals are able to regulate
connectivity independent of signals from the cell body, second that synapses exist in a dynamic
state, poised to shift from stability to loss by activating intrinsic mechanisms and molecules, and
third that local purines acting at purinergic receptors can trigger these events. A role for ATP
receptors in this is not surprising since they are frequently activated during cellular injury, when
adenosine tri-phosphate is released from damaged cells. Local control demands that the elements
necessary to drive retraction are constitutively present. We hypothesize that pre-existing scaffolds
of molecular motors and cytoskeletal proteins could provide the dynamism required to drive such
structural changes in nerve terminals in the absence of the cell body.
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Retraction of nerve terminals is a fundamental event in
the development and maintenance of the nervous system
[1,2], occurring when exuberant neuronal projections are
pared back by activity-dependent processes. These events
have been extensively studied at the neuromuscular junc-
tion (NMJ) during development [3,4], re-innervation [5]
and following axotomy [6]. Here, competing nerve termi-
nals at muscle motor endplates are withdrawn bouton-by-
bouton in an apparently controlled, piecemeal fashion
until the last bouton withers and is re-absorbed into the
parent axon [4,7,8]. However, relatively little is known
about the cellular mechanisms that govern progressive
nerve terminal retraction. This information is particularly
pertinent since nerve terminal loss is emerging as a key
early event in many neurodegenerative diseases tradition-
ally thought of as disorders of cell bodies [9-12]. In fact
nerve terminal loss has now been observed as the earliest
event in spinal muscular atrophy [13,14], progressive
motor neuropathy [15,16], amyotrophic lateral sclerosis
[17], motor neurone degeneration and SOD1 over expres-
sion [16]. Additionally, in the CNS Huntington's [18] and
Alzheimer's [19] diseases both show early nerve terminal
loss.
Available data points to a degree of synaptic independ-
ence in the retraction of individual synaptic connections.
Observations of single motor units during developmental
synapse elimination reveal three quite separate popula-
tions of nerve terminals: stable, actively withdrawing and
actively enlarging [3,12] and it is difficult to envisage how
a single cell soma could directly co-ordinate this range of
actions in different parts of its terminal arbour. Adult
axons and terminals appear to contain little if any
machinery for protein synthesis, but the first signs of
regenerative sprouting occurs within a day of axotomy
[20,21], which appears too rapid for communication
from the site of injury to the cell body and back, even by
fast axonal transport. Neonatal synapse elimination can
proceed subsequent to axotomy [6] and co-ordinated
structural changes at presynaptic nerve terminals (retrac-
tion) can occur in the absence of parent cell somas. Axons
disconnected from their cell bodies in vitro can assemble
new growth cones at lesion sites [22-24] and transected
axons are able to mount a regenerative response in the
absence of cell somas [25]. Taken together these data sug-
gest that the machinery necessary to drive synapse loss
(and re-growth) may be constitutively present in the nerve
terminal and axon and that communication with the cell
body is unnecessary. Although other evidence, primarily
from the hippocampus, demonstrates that long-term
alterations in synaptic strength at subsets of neurones in a
synaptic field may be driven by pre-existing or newly syn-
thesised plasticity related proteins which differentially
bind to synapses dependent upon their level of activity.
This is thought to be regulated by synaptic tagging [26],
where single synapses can show independent behaviour.
In this study we show that nerve terminal retraction can be
triggered in the absence of neuronal cell bodies by the
extracellular application of an ATP analogue. The nature
of the nerve terminal retraction does not resemble Walle-
rian or Wallerian-like degeneration; rather it resembles
'dying back' neuropathies and synapse elimination.
Results
BzATP triggers the rapid loss of nerve terminals in the 
absence of cell bodies
ATP is released following injury, signals local damage [27]
and low-sensitivity receptors tuned to respond to such
pathophysiological concentrations of ATP are present on
motor nerve terminals [28,29]. We therefore tested the
effect of activation of ATP receptors at neuromuscular
junctions with a relatively stable ATP analogue, BzATP.
Preparations consisting of axotomised and isolated
peripheral nerve and skeletal muscle were dissected and
placed into oxygenated physiological saline, after a brief
(15 min) pulse of BzATP (100 μM) they were returned to
the oxygenated saline solution for 165 min. Preparations
were then fixed and immunostained for components of
nerve terminals (neurofilament and synaptic vesicles) and
muscle endplates (acetylcholine receptors). BzATP-treated
preparations demonstrated a variety of morphologies;
typically endplates were either fully occupied by intact
nerve terminals (Occupied: Fig 1a, arrow) or devoid of
any innervating nerve terminal (Unoccupied: Fig 1a, b,
arrowheads). Intact presynaptic axons were often seen
immediately adjacent to unoccupied endplates (Fig 1b).
Other terminals appeared to lie between these two
extremes and had lost either a minority (Fig 1c, asterisk)
or a majority (Fig 1d, asterisks) of nerve terminal boutons
(Intermediate: Fig 1b–d). Remaining nerve terminals and
nerve terminal boutons appeared healthy, maintained
connectivity with the intramuscular nerve and were indis-
tinguishable from those seen in control (300 min physio-
logical saline) preparations (Fig 1e).
Quantitative data taken from the preparations described
above are shown in figure 2. In summary, data for experi-
mental (BzATP-treated, solid bars) preparations were as
follows: occupied, 54 ± 3%; intermediate, 22 ± 3%; unoc-
cupied, 24 ± 2%, N = 4, n = 350. These data demonstrate
considerable nerve terminal loss, with almost half of the
neuromuscular junctions showing characteristics consist-
ent with retraction. By comparison control preparations
(open bars), which were maintained in physiological
saline for 180 min had fully occupied muscle endplates
(Occupied, 100%, N = 6, n = 550) and were indistinguish-
able from preparations fixed immediately after dissection
(Occupied, 100%, N = 3, n = 150). The reduction in fullyPage 2 of 10
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BzATP was significantly different from control prepara-
tions (P < 0.001, Kruskal-Wallis with Dunn's post hoc
multiple comparison test).
During the course of these experiments we occasionally
found intact nerve terminals associated with fragmented
endplates (Fig 3a, arrowheads), or lying above muscle
fibres where no muscle endplate was present (Fig 3b). We
also found several examples of nerve terminals which
appeared to be in the process of fragmentation, either in
isolation (Fig 3c upper) or possibly in conjunction with
endplates (Fig 3c lower, Fig 3d). Similar appearances were
not seen in control preparations. These junctions consti-
tuted less than 1% of the total and were classified as inter-
mediate for the purposes of quantification.
BzATP acts at presynaptic purinoceptors to trigger nerve 
terminal loss
ATP acts at a range of purinoceptors, though our previous
studies have only been able to demonstrate P2X7 receptor
subunits (P2X7RS) on motor nerve terminals [29]. How-
ever, there is evidence for the presence of P2Y receptor
subunits on Schwann cells [30] and muscle fibres [31].
We therefore further investigated the possible involve-
ment of purinoceptors in the BzATP-induced response
Nerve terminal bouton loss in response to an extracellular cue occu s i  the abse ce of euronal cell bodiesFigure 1
Nerve terminal bouton loss in response to an extra-
cellular cue occurs in the absence of neuronal cell 
bodies. All preparations were fixed in 4% paraformaldehyde 
prior to immunostaining for neurofilament 165 and SV2 
(green: axons and terminals), visualised with a Cy2-conju-
gated secondary antibody and co-stained with TRITC-αBTX 
(red: muscle endplates), 165 min after a 15 min BzATP pulse 
(100 μM). Both 'occupied' (a: arrow) and 'unoccupied' (a: 
arrowhead) endplates were present, as were unoccupied 
endplates with intact presynaptic axons (b). Many terminals 
appeared to be in the process of retraction resulting in minor 
(c: asterisk) or major (d: asterisks) regions of unoccupied 
endplates. These were classified as 'intermediate' in subse-
quent data. Control nerve/muscle preparations, which were 
maintained in physiological saline for up to 300 min, showed 
no visible signs of degeneration or retraction of nerve termi-
nals (e). Scale bar a-e = 15 μm
Nerve terminal loss appears to be triggered via activation of purinoc ptorsFigure 2
Nerve terminal loss appears to be triggered via acti-
vation of purinoceptors. Figure showing the proportion of 
occupied, intermediate and unoccupied muscle endplates 
present in: 300 min control (open bar); 165 min subsequent 
to a 15 min BzATP pulse (100 μM: filled bar); 165 min subse-
quent to a 15 min BzATP pulse (filled bar) in the presence of 
Brilliant Blue G (a selective P2X7 receptor antagonist: BBG, 
1 μM: broad diagonal cross-hatching); 165 min subsequent to 
a 15 min BzATP pulse in the presence of Reactive Blue 2 
(which blocks P2Y and P2X receptor subunits: 100 μM, RB2: 
narrow diagonal cross-hatching) or 165 min subsequent to a 
15 min BzATP pulse in the presence of Suramin (a broad 
spectrum P2 receptor agonist: 100 μM: stipple). All data is 
mean ± SEM of multiple repeats (see text for n values).Page 3 of 10
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with a selective antagonist for P2X7RS, Brilliant blue G
(BBG: 1 μM) either partially blocked or slowed BzATP-
induced nerve terminal loss (occupied, 74 ± 4%; interme-
diate, 25 ± 5%; unoccupied, 0%, N = 3, n = 300). Reactive
Blue 2 (100 μM), which is reported to block P2Y and
P2X7 receptor subunits, completely blocked BzATP-
induced nerve terminal retraction (occupied, 100%, N =
3, n = 300). Complete block of BzATP-induced retraction
was also obtained with the broad-spectrum P2 antagonist
Suramin (100 μM: occupied, 100%, N = 2, n = 200).
Quantitative data from these experiments are summarized
in Figure 2.
Remaining axons and nerve terminals transmit action 
potentials and recycle neurotransmitter
The failure to propagate compound action potentials [32]
and to recycle neurotransmitter are amongst the first signs
of neuronal degeneration. We therefore used the vital flu-
orescent dye RH414 to label nerve terminals 150 min sub-
sequent to a 30 min exposure to BzATP (100 μM).
Loading is carried out by electrical stimulation of the
intramuscular nerve, which generates nerve action poten-
tials, which then propagate into the nerve terminal and
trigger vesicle release. Imaging was carried out 60 min
after dye loading to allow for washout of unbound dye
(240 min in total). We were able to label synaptic vesicles
in motor nerve terminals (Fig 4), which is an indirect
measure of their physiological integrity.
Early ultrastructural events at neuromuscular junctions are 
consistent with nerve terminal retraction
To further investigate ultrastructural events during the
rapid-onset retraction events observed following applica-
tion of BzATP we carried out immuno-electron micros-
copy. Isolated peripheral nerve and skeletal muscle
preparations were incubated in BzATP (100 μM) for 30
min, immediately fixed and immunostained for P2X7
receptors. Nerve terminal boutons were immunopositive
for P2X7 receptors and exhibited evidence consistent with
retraction from post-synaptic sites. This included: dilation
of synaptic clefts and appearance of mega-omega profiles
in the pre-junctional, pre-synaptic membrane (asterisk,
Fig 5a); presence of small cellular profiles intervening
between pre and post synaptic membranes within the syn-
aptic cleft (Fig 5b, arrowhead); detachment of terminal
boutons from the postsynaptic membrane and insertion
of terminal Schwann cell process between pre and postsy-
naptic elements (arrow, Fig 5c). In each case there was no
evidence of alteration to the post-synaptic membrane. The
synaptic gutters appeared unaltered and widening of the
synaptic cleft appeared to be entirely due to movement of
the presynaptic nerve terminal away from the surface of
the post-synaptic muscle fibre membrane. The ultrastruc-
tural changes observed were not consistent with Wallerian
degeneration, as axons were intact and withdrawing nerve
terminal boutons contained intact mitochondria and
were not vacuolated [33-35]. Control preparations that
were fixed after 30 min incubation in physiological saline
displayed normal morphology including: narrow synaptic
clefts, intact mitochondria (Mi), densely packed synaptic
vesicles (SV) and overlying terminal Schwann cells (TSc,
Fig. 5d). These studies clearly indicate that ultrastructural
events consistent with retraction of nerve terminal bou-
tons begin as little as 30 minutes after the addition of
BzATP.
To further investigate events subsequent to BzATP incuba-
tion, we introduced a 60 min drug washout period after
the 30 min BzATP incubation, but prior to fixation. These
showed further evidence of ongoing nerve terminal loss
including vacant areas of muscle endplate with no overly-
ing nerve terminal bouton (Fig 6a, arrows) and retracting
boutons wrapped in Schwann cell processes (Fig 6b). The
presence of intact mitochondria and absence of cytoplas-
mic vacuolation in neurones, coupled with the presence
Some nerve terminals and muscle endplates fragmented in response to BzATPFigure 3
Some nerve terminals and muscle endplates frag-
mented in response to BzATP. All preparations were 
fixed in 4% paraformaldehyde prior to immunostaining for 
neurofilament 165 and SV2 (green: axons and terminals), vis-
ualised with a Cy2-conjugated secondary antibody and co-
stained with TRITC-αBTX (red: muscle endplates), 165 min 
after a 15 min BzATP (100 μM) pulse. Nerve terminals asso-
ciated with either fragmented (a), or absent (b) muscle end-
plates were seen, as were fragmented nerve terminals 
contacting either apparently normal (c), or fragmented end-
plates (c, d). Scale bar a, d = 15 μm, b, c = 30 μmPage 4 of 10
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that neither had degenerated during the course of the
extended experimental window. Maintaining untreated
(control) preparations for this extended period (90 min)
prior to fixation did not result in any obvious changes in
gross or fine structure (Fig 6c).
Discussion
In this study we demonstrate that in preparations where
distal nerve axons, terminals and associated skeletal mus-
cle fibres, BzATP can trigger the retraction of nerve termi-
nals from post-synaptic muscle fibre endplates even
though they are no longer connected to their parent cell
bodies. The events triggered most closely resemble retrac-
tion events during neuromuscular synapse elimination.
This action of BzATP appears to be mediated by presynap-
tic P2X7 receptors.
Isolated axons and terminals can undergo dynamic cellular 
re-arrangements
In these experiments we show that a brief pharmacologi-
cal signal can trigger rapid and significant morphological
events in cell fragments consisting of isolated nerve termi-
nals and attached distal axon stumps. We suggest that the
morphology of these events most closely resembles nerve
terminal retraction during developmental synapse elimi-
nation [4,6,33,36], following nerve section in the slow
Wallerian degeneration mouse [6] and in motor neurone
disease [17]. We also observed fragmentation of pre and/
or postsynaptic sites at a small number of neuromuscular
junctions and interestingly similar synaptic responses
have also been observed during developmental synapse
elimination [37] and in mouse models of spinal muscular
atrophy [14]. Therefore we suggest that the events seen
here are part of the normal physiological/pathophysiolog-
ical repertoire of neurones, which have been triggered by
activation of pre-synaptic purinergic receptors. It will be
interesting to determine the exact rate and timecourse of
the events described here by using confocal and timelapse
imaging. However, this may not in fact further illuminate
the underlying molecules and mechanisms at play. Signif-
icantly, during the course of these studies we found no
Intact nerve terminals were capable of releasing and recycling synaptic vesicles subsequent to th  addition of BzATPFigure 4
Intact nerve terminals were capable of releasing and 
recycling synaptic vesicles subsequent to the addition 
of BzATP. The fluorescent vital styryl dye RH414 was used 
to label recycling synaptic vesicles by indirect nerve stimula-
tion at the end of the 180 min experimental period and just 
prior to fixation. Remaining nerve terminals were brightly 
labelled with the dye (a) and fully occupied underlying motor 
endplates (b). A grayscale image of a single nerve terminal is 
shown in panel a, while the same terminal (coloured green) is 
seen to fully occupy a singe motor endplate (coloured red) in 
the composite image. Scale bar = 10 μm
Ultrastructural events indicate that nerve terminal loss progresses by r tractioFigu  5
Ultrastructural events indicate that nerve terminal 
loss progresses by retraction. Nerve and muscle prepa-
rations were fixed for immuno-electron microscopy and 
labelled for P2X7 receptor subunits (dark DAB reaction 
product) to facilitate localisation. When preparations were 
fixed and immunostained subsequent to a 30 min BzATP 
(100 μM) pulse frequent abnormal appearances were found. 
These included; widened synaptic clefts with the appearance 
of mega-omega profiles (asterisk) (a), fine processes of termi-
nal Schwann cells invaded the synaptic cleft (b: arrowhead), 
boutons which were detached from the muscle endplate and 
where terminal Schwann cell processes had come to inter-
vene between the two (c: arrow). In control nerve muscle 
preparations incubated in physiological saline for 30 min 
prior to fixation and immunostaining (d), motor nerve termi-
nal boutons contained reaction product for P2X7RS, intact 
mitochondria (Mi), densely packed synaptic vesicles (SV), 
were closely apposed to muscle endplates (EP) and overlain 
by terminal Schwann cell (tSc). a, b, d = 500 nM, c = 1 μMPage 5 of 10
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to and including 5 hr after axons were cut during dissec-
tion. This agrees with our previous findings which indi-
cated that Wallerian degeneration does not begin until at
least 12 hours after dissection [6]. Specifically, we saw no
evidence of terminal Schwann cells engulfing degenerat-
ing nerve terminal boutons in-situ, mitochondrial degra-
dation or cytoplasmic vacuolation [32,38], which would
indicate degenerative events. We did however, see par-
tially occupied 'intermediate' junctions (Fig 1c, d) and
intact nerve terminal boutons which had apparently with-
drawn from post-synaptic sites (Fig 5c), both of which are
atypical of degenerative changes, and characteristic of
retraction events. Occasionally we found evidence of frag-
mented or absent muscle endplates, associated with intact
or fragmented nerve terminals. As P2X2 receptor subunits
have recently been shown to have a role in the formation
of neuromuscular junctions [39], it is possible that this
indicates a direct effect on post-synaptic structures or
nerve to muscle communication pathways.
Several other groups have described dramatic morpholog-
ical events at the neuromuscular junction subsequent to
insult. Is it likely then that the events described here are
simply a response to toxic insult? Addition of a compo-
nent of Black Widow Spider venom, α-latrotoxin [40],
triggers massive exocytosis of vesicles which produce pre-
synaptic 'arches', similar in appearance to the mega-
omega profiles described here. However, these junctions
recover and do not progress to disconnection of nerve ter-
minals from muscle fibre membranes or insertion of
Schwann cell membranes into synaptic clefts. Blocking of
axoplasmic flow by the addition of colchicine [41] after a
period of days leads to an increased density of synaptic
vesicles, mitochondrial disruption, retraction and
Schwann cell wrapping of nerve terminal boutons. How-
ever, we did not see mitochondrial damage or obvious
signs of synaptic vesicle accumulation, if anything vesicles
were slightly depleted compared to control preparations.
In addition, colchicine produces gross changes in the
post-synaptic muscle fibre membrane associated with the
loss of junctional folds as the nerve terminal withdraws.
Complement-mediated anti-ganglioside attack [42] pro-
duces electron lucent nerve terminals with damaged mito-
chondria, invasion of Schwann cells into the synaptic cleft
and wrapping of nerve terminal boutons. We did not see
evidence of such degenerative changes, though we did
observe similar insertion and wrapping of nerve terminal
boutons by Schwann cell processes, but this is also a com-
mon feature of synapse elimination [33,36,37]. All of
these situations have disruption of mitochondria as a sig-
nificant, and often early event, which we did not observe
following treatment with BzATP. Further, nerve terminals
exhibited selective vulnerability to the BzATP pulse, which
is not the case in toxic injury. We would predict that sim-
ilar events could be demonstrated in vivo and on non-
axotomised nerve terminals [6], and this is an avenue
which will be pursued in future studies.
Activation of P2 receptors trigger nerve terminal loss
We show that a stable analogue of ATP triggers structural
changes in nerve terminals. BzATP is relatively selective
for P2X7RS, but more importantly this is so far the only
member of the ionotropic family of P2X receptors
Ultrastructural changes compatible with nerve terminal retraction continue after removal of BzATPFigure 6
Ultrastructural changes compatible with nerve terminal retraction continue after removal of BzATP. When 
nerve/muscle preparations were exposed to a 30 min BzATP (100 μM) pulse followed by a 60 min washout period prior to fix-
ation, many nerve terminal boutons were in advanced states of retraction. This was manifested as vacant regions of muscle 
endplate (a) and vesicle-filled boutons that were clearly wrapped by Schwann cell processes (b). Control preparations main-
tained in physiological saline for 90 min (c) were identical in appearance to freshly fixed preparations (compare with figure 5a). 
Scale bar a, b = 1 μM, c = 500 nMPage 6 of 10
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have however, been described on muscle fibres [39] and
Schwann cells [43]. The validity of tools used to demon-
strate P2X7RS on neurones have been questioned, but the
current consensus is that the original reports [28] are accu-
rate [44]. We suggest that BzATP acts, at least in part, on
P2X7RS. BzATP-induced nerve terminal retraction was
incompletely prevented by the P2X7RS selective blocker
BBG, but completely prevented by RB2 and Suramin,
which block both P2X and P2Y receptor, subtypes. There-
fore it is likely that BzATP also targets P2Y receptors in
these experiments. We do not know to what extent P2X
and P2Y receptors work via common or separate signal-
ling pathways and currently available drugs are not suffi-
ciently selective to allow us to unravel the relative
involvement of these sub-families at the present time.
Interestingly, P2Y receptors have been reported on both
Schwann cells [45] and muscle fibres [46], which could
provide potential pathways for the observations of
Schwann cell invasion and endplate dismantling. Activa-
tion of P2X7RS can open a cation-permeable ionotropic
channel or a large (membrane permeating) pore [47]. We
have previously demonstrated that BzATP does not open
a large pore at motor nerve terminals by simultaneous
incubation in a solution of the membrane-impermeant
fluorochrome, 6-carboxyfluoroscein (see figure 5 in [29]).
This suggests that if activation of P2X7RS is a key event in
this response, it is the ionotropic channel and not the
membrane permeabilising large pore that is responsible.
When might ATP rise to sufficient levels to trigger these
responses in vivo? First, following direct muscle trauma
when loss of membrane integrity leads to the release of
muscle sarcoplasm containing approximately 8 mM ATP
[48] into the extracellular space. Second, during tissue
ischaemia when both neurones and muscle fibres release
ATP [49,50] and ionic gradients across cellular mem-
branes collapse resulting in a fall in the concentrations of
extracellular divalent cations [51]. This combination of
factors facilitates P2X7RS activation by removal of a rest-
ing cation-block [43,52]. One other group have described
what appear to be similar retraction events following
ischaemia in a preliminary report [53], and another have
implicated P2X7RS in hypoxic damage at synapses in the
CNS [54], hinting that ATP could be a key factor in
hypoxic damage. It is interesting to note that P2 receptor
antagonists improve recovery after spinal cord injury [55],
pointing to a possible general mechanism for dynamic
rearrangement of synapses through nerve terminal loss
following chronic or acute injury.
Autonomous events in nerve terminals
We have demonstrated that BzATP triggers a controlled
retraction of nerve terminals from post-synaptic sites.
Importantly, this occurs in isolated nerve-muscle prepara-
tions where all connectivity with the parent motor neu-
rone cell bodies has been abolished. The heterogeneity of
synaptic responses recorded is similar to events described
in single motor units during developmental synapse elim-
ination [4,35] and following axotomy in mutant slow
Wallerian degenerating (Wlds) mice [6]. These observa-
tions, taken together with other data [4,6], support the
notion that nerve terminals are autonomous or 'compart-
mentalised' [56], each compartment containing specific
elements/processes enabling them to respond in different
ways to environmental signals. If local, compartmental-
ised processes are important in retraction events, how are
they controlled? Changes in cell shape require alterations
to the cytoskeleton and it seems unlikely that new
cytoskeletal elements could be generated and/or assem-
bled within the time frame of these experiments, espe-
cially in the absence of neuronal cell bodies. An attractive
hypothesis therefore is that sufficient cytoskeletal ele-
ments to drive nerve terminal retraction are constitutively
present in distal axons and terminals and that re-arrange-
ment of these drive retraction events. Non-muscle
myosins IIA and IIB drive neurite elongation and retrac-
tion in culture [57,58] and we have previously shown that
these are present in motor nerve terminals [59]. Here a
pre-assembled 'molecular clutch' [60] regulated by the dif-
ferential activation of opposing myosin motors by kinases
could drive cytoskeletal rearrangement, and therefore
morphological change, without the requirement for gen-
eration of new cytoskeletal elements. It remains unclear
how purinergic receptors might be linked to the cytoskel-
eton, but evidence exists to link similar pathways in other
systems. Extracellular purines acting on membrane-
bound receptors trigger dissagregation of the actin
cytoskeleton in the WRK-1 (mouse mammary tumour)
cell-line. This may be related to differential activation of
molecular motors [61]. Proteomic analysis of the P2X7R
indicates several cytoskeletal elements present within the
receptor complex [62] and one of these, supervillin, binds
to actin and non-muscle myosin II. Supervillin is an
important adapter protein in the organisation of attach-
ments of the cytoskeleton to dynamic regions of mem-
branes [63] which could drive shape changes at nerve
terminals.
Conclusion
In summary, we provide evidence that following discon-
nection from their parent cell bodies, activation of P2X7
receptors on nerve terminals by BzATP triggers synaptic
retraction. This retraction closely resembles similar events
occurring during synapse elimination and motor neurone
disease. We suggest that molecules and mechanisms con-
stitutively present in the distal axon and terminal are suf-
ficient to drive this retraction response. Further, we
speculate that signals from the parent cell soma may notPage 7 of 10
(page number not for citation purposes)




Adult C57BL/6 mice were killed by CO2 intoxication, and
intact preparations of lumbrical muscles, plantaris tendon
and sciatic/tibial nerves were dissected and pinned out at
resting length in Sylgard-lined Petri dishes containing
oxygenated (95%O2/5%CO2), calcium and magnesium
free physiological saline (122.4 mM NaCl, 5 mM KCl, 0.4
mM NaH2PO4, 23.8 mM NaHCO3, 5.6 mM Glucose, 5.5
mM Hepes, pH 7.2–7.4) at room temperature. These were
transferred to oxygenated physiological saline as above,
and any muscles which failed to twitch in response to
nerve stimulation were excluded from further assay. Prep-
arations were either maintained throughout in oxygen-
ated physiological saline or alternatively in the same
saline supplemented with several different purinergic ago-
nist and antagonists. Purine receptor agonists and antago-
nists used were as follows: 2'-3'-O-(4-benzoylbenzoyl)-
adenosine 5'-triphosphate (BzATP: 100 μM), Brilliant
blue G (BBG: 1 μM), Reactive Blue 2 (RB2: 100 μM),
Suramin (100 μM). All experiments began within 60 min
of animal sacrifice.
After the experimental period (3 hrs), preparations were
fixed in 4% paraformaldehyde for 30 mins and stained for
immunofluorescence microscopy. Synaptic vesicles and
neurofilaments were labelled with a combination of SV2
(1:500) and NF165 (1:250, developed by T.M. Jessel and
J. Dodd, and obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of
NICHD and maintained by the University of Iowa,
Department of Biological Sciences, Iowa City, USA), and
visualised with Cy2- (1:200, donkey anti mouse: Jackson
laboratories, USA) secondary antibody. Post-synaptic ace-
tylcholine receptors were labelled with tetramethyl rhod-
amine isothiocyanate conjugated ãbungarotoxin (5 μg/
ml, TRITC-a-BTX: Molecular Probes, Leiden). Slides were
coverslipped in 2.5% n-propyl gallate in glycerol and
viewed with epifluorescence illumination. In preliminary
experiments we determined that a 15 min pulse of BzATP
was the optimum trigger for nerve terminal retraction.
Electron microscopy
Mice were killed and handled as above, but in this case
intact preparations of flexor digitorum brevis muscles and
associated sciatic/tibial nerve were dissected and placed
Immediately after dissection into freshly prepared and
oxygenated physiological saline. Addition of chemicals
began within 60 minutes of animal sacrifice. BzATP (100
μM) was added for 30 min and preparations were fixed in
buffered 4% paraformaldehyde/0.2% glutaraldehyde, pH
7.2 either immediately or subsequent to a 60 min wash-
out period. Muscles were fixed and labelled for electron
microscopic localisation of P2X7 receptor subunits
(P2X7RS) as previously described [29].
Vital imaging
Preparations were treated identically to those above,
except at the end of the 3 hr period, they were vitally
labeled and imaged. Preparations were loaded with the
vital styryl dye RH414 (10 μg/ml; Molecular Probes) in
physiological saline solution by nerve stimulation (supra-
threshold 0.1 msec pulse trains delivered at 10 Hz for 10
min to the intercostal nerve via asuction electrode), fol-
lowed by at least 1 hr washing in oxygenated physiologi-
cal saline. Preparations were transferred to the microscope
stage and terminals were imaged.
Quantification
25 sequentially identified endplates from randomly ori-
ented immunostained lumbrical muscles were identified
and quantified for the degree of congruence between over-
lying nerve terminal and muscle endplate from four mus-
cles per hindfoot. Three categories were used; 'occupied',
denoting complete occupancy; 'intermediate', where
either endplate was partially occupied by nerve terminal
or was fragmented; 'unoccupied', where no nerve terminal
was present at the endplate. Occasionally, damaged mus-
cle fibres or unusually deep endplates were difficult to
accurately assess, and were discarded from the data set.
Data are presented as mean ± SEM, N = number of mice,
n = number of endplates. GraphPad Prism (Graphpad
software) was used to carry out statistical tests.
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